Mucus

New Campaign Highlights How Certain Jobs Can Increase a Person's Risk for Lung Disease

Retrieved on: 
Tuesday, April 9, 2024
Pneumonia, Emphysema, Bronchitis, Disease, Tobacco, Agriculture, Risk, Urinary tract infection, Spirometry, Fatigue, Smoke, Quality of life, Sputum, Dust, Mucus, Smoking, Wheeze, American Lung Association, COPD, Air pollution, Workplace, Phlegm, Ageing, Mining, Nursing

CHICAGO, April 9, 2024 /PRNewswire/ -- Chronic obstructive pulmonary disease (COPD) impacts 11.7 million people living in the U.S. While smoking is a significant risk factor for the disease, long-term exposure to dust, chemicals, fumes and vapors from the workplace may also lead to COPD. To help people identify workplace risk factors and encourage them to speak with their healthcare provider if they are experiencing symptoms, the American Lung Association is launching a campaign to raise awareness for occupational COPD. 

Key Points: 
  • While smoking is a significant risk factor for the disease, long-term exposure to dust, chemicals, fumes and vapors from the workplace may also lead to COPD.
  • COPD, which includes chronic bronchitis and emphysema, is a long-term lung disease that makes it hard to breathe.
  • Many workplaces may expose workers to risk factors for COPD, but the leading job types that increase risk for chronic lung disease include agriculture, mining and manufacturing.
  • Early treatment of a chronic lung disease, including reducing the exposure, can help lead to better health outcomes.

Orphan designation: (6aR,10aR)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydrocannabinol-9-carboxylic acid- Treatment of cystic fibrosis, 14/10/2016 Positive

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Diagnosis, Civil service commission, Absorption, Lower respiratory tract infection, Exercise, Cell, Infection, DSM-IV codes, Inflammation, Patient, Committee, Cystic fibrosis, Knowledge, Digestion, Regulation, Bacteria, Food, EMA, IRIS, Anti-inflammatory, Mucus, CB2, European, COMP, Pancreas, Sponsor, Ivacaftor, European Commission, Safety, CFTR, Marketing, Medicine, Pharmaceutical industry

Orphan designation: (6aR,10aR)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydrocannabinol-9-carboxylic acid- Treatment of cystic fibrosis, 14/10/2016 Positive

Key Points: 


Orphan designation: (6aR,10aR)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydrocannabinol-9-carboxylic acid- Treatment of cystic fibrosis, 14/10/2016 Positive

Infinant Health Announces Submission of Orphan Drug Designation Application

Retrieved on: 
Tuesday, April 2, 2024
ODD, Bifidobacterium longum, Health, Disease, Incidence, Partnership, Risk, Necrotizing enterocolitis, Health maintenance organization, Biomarker, Disorder, Milk, Mortality, Bacteria, Infant, Death, United, NEC, Mucus, Marketing, FDA, Food, Pharmaceutical industry

DAVIS, Calif., April 2, 2024 /PRNewswire/ -- Infinant Health, a privately-held company focused on changing the trajectory of human health, one baby at a time, announced it has filed an application with the U.S. Food and Drug Administration (FDA) to receive Orphan Drug Designation (ODD) for its drug candidate INF108 for the prevention of necrotizing enterocolitis in pre-term infants.

Key Points: 
  • DAVIS, Calif., April 2, 2024 /PRNewswire/ -- Infinant Health, a privately-held company focused on changing the trajectory of human health, one baby at a time, announced it has filed an application with the U.S. Food and Drug Administration (FDA) to receive Orphan Drug Designation (ODD) for its drug candidate INF108 for the prevention of necrotizing enterocolitis in pre-term infants.
  • The FDA grants Orphan Drug Designation status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics.
  • Orphan Drug Designation would qualify INF108 for certain benefits and incentives, including seven years of marketing exclusivity if regulatory approval is ultimately received for the designated indication, potential tax credits for certain activities, eligibility for orphan drug grants, and the waiver of certain administrative fees.
  • The receipt of Orphan Drug Designation status does not change the regulatory requirements or process for obtaining marketing approval.

Gut bacteria and the immune system: How aging changes the microbiome and can lead to ‘inflammaging’

Retrieved on: 
Wednesday, April 3, 2024
Research, Inflammation, Inflammaging, Health, Red meat, Vitamin, Bacillota, Nutrient, Archaea, Cell, Environment, Disease, Infection, Homeostasis, Probiotic, Risk, Dysbiosis, Gastrointestinal tract, Extrapyramidal system, Tissue, Actinomycetota, Fungus, Bacteria, Virus, University, Life, Pseudomonadota, Type 2 diabetes, Diet, Nutritional science, Mucus, Immune system, Cellular senescence, Family, Stomach, Antigen, Type 2, Vaccine

Research has shown that changes to the composition and diversity of the microorganisms in the gut may explain these differences in immune system aging.

Key Points: 
  • Research has shown that changes to the composition and diversity of the microorganisms in the gut may explain these differences in immune system aging.
  • However, as the composition of our gut microbiome changes with age, a low level of inflammation can become constant throughout the body.
  • Let’s take a closer look at the gut microbiome and how it changes with age.

Gut microbiome imbalances in older adults

  • In fact, compared to other parts of the body, the gut microbiome has the largest number of bacteria.
  • In a healthy gut microbiome, there are four dominant families (or phyla) of microorganisms, including Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria.
  • Firmicutes and Bacteroidetes make up around 80 to 90 per cent of the gut microbiota in the digestive tract.
  • Over time, the shortage of beneficial bacteria such as Firmicutes in older adults starts to compromise the integrity of their intestinal barrier, causing it to become leaky.

How inflammaging works

  • Inflammaging creates an environment that is prone to inflammation, which is caused and maintained by several factors.
  • These can include microorganism imbalances in the intestines (microbial dysbiosis), psychological stress, physical inactivity, poor nutrition and chronic infections.

Maintaining a healthy balance of gut microbiota

  • More specifically, probiotics help improve the function of the intestinal barrier and regulate immune responses by modifying the composition of the gut microbiome.
  • It is clear that the immune system has an intricate relationship with the gut microbiome.
  • A healthy and well-balanced gut microbiome will strengthen the intestinal barrier, which helps to reduce inflammation throughout the body and support the immune system.
  • To achieve this, it is important to maintain a healthy and well-balanced lifestyle as we grow older.


Narveen Jandu does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Herbal medicinal product: Foeniculi dulcis fructusArray, F: Assessment finalised

Retrieved on: 
Tuesday, March 12, 2024
Key, Collection, Fungus, Allergy, European Commission, Capsule, Woman, Committee, Respiratory system, Cramp, Mucus, Growth, Rat, Skin, Pregnancy, Date, Seed, Mouth, Lactation, Urinary system, Safety, Fennel, Civil service commission, Common, Rabbit, Fruit, Medicine, Diagnosis, Tablet, Community, Herbal medicine, Spice

Herbal medicinal product: Foeniculi dulcis fructusArray, F: Assessment finalised

Key Points: 


Herbal medicinal product: Foeniculi dulcis fructusArray, F: Assessment finalised

Actress Jane Seymour and Insmed Raise Awareness of "Unseenism" and Empower People to Speak Up When It Comes to Their Health

Retrieved on: 
Wednesday, February 28, 2024
Television, Woman, Bronchiectasis, Education, Mucus, Ageing, Hope, Communication, Prevalence, Health, Bacteria, Human, Patient, Flare, Diagnosis, Respiratory disease, Nursing

"In both my television and film roles and in real life, I've always tried to push back against the typical notions of aging and feeling unseen.

Key Points: 
  • "In both my television and film roles and in real life, I've always tried to push back against the typical notions of aging and feeling unseen.
  • Being older shouldn't mean you are no longer valuable or relevant," said Seymour.
  • The survey of over 2,000 participants, conducted by Insmed, aimed to uncover how "Unseenism" can shape the health decisions of people aged 40+ years.
  • 72% said being knowledgeable about their health makes them feel empowered to speak up with healthcare providers.

InventHelp Inventor Develops Product to Relieve a Cold and Mucus (RKH-555)

Retrieved on: 
Monday, February 19, 2024
Mucus, Nasal cavity, Head, Sale, Common, SWEAT, Multimedia, Suite, COLD

I thought others could benefit from this process," said an inventor, from Rocky Mount, N.C., "so I invented the COLD SWEAT.

Key Points: 
  • I thought others could benefit from this process," said an inventor, from Rocky Mount, N.C., "so I invented the COLD SWEAT.
  • My design would help eliminate colds and sinus problems by breaking up mucus that is found in the sinus and chest cavities."
  • The patent-pending invention provides effective relief from a cold by breaking up mucus found in the sinus and chest cavities.
  • In doing so, it would emit moisture/heat into the nasal cavity and atop the chest in order to break up mucus associated with colds.

InventHelp Inventor Develops Specially Formulated Health Supplement (DAL-366)

Retrieved on: 
Thursday, February 15, 2024
Mucus, Suite, Bacteria, COVID-19, Arthritis, Sale, Multimedia, Immune system, Inflammation

I thought there could be an all-natural and easy-to-consume supplement to help with various ailments," said an inventor, from Fort Worth, Texas, "so I invented the PINEAPPLE.

Key Points: 
  • I thought there could be an all-natural and easy-to-consume supplement to help with various ailments," said an inventor, from Fort Worth, Texas, "so I invented the PINEAPPLE.
  • My nutritious formula could increase energy, boost the immune system, and help relieve the symptoms of arthritis, COVID-19 and its variants, inflammation, etc."
  • The invention provides an all-natural supplement to help heal the body of various ailments, bad bacteria, mucus, etc.
  • As a result, it may help boost the immune system and it could provide added health benefits.

Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis

Retrieved on: 
Thursday, February 15, 2024
Therapy, LNP, Liver, MB, CRISPR, Gene editing, Messenger, Intellia Therapeutics, Recode, Cystic fibrosis, Mucus, NTLA, Lung, DSM-IV codes, Respiratory failure, Cell, CFTR, Patient, Medicine, Tissue, Research, DNA, Vaccine

and MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, and ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis (CF).

Key Points: 
  • and MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, and ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis (CF).
  • Intellia will be responsible for the design of the editing strategy and research-grade components for the investigational therapies.
  • “This collaboration provides further validation of ReCode's SORT LNP platform to deliver diverse gene editing modalities to specific cells and tissues.
  • By combining our highly synergistic technologies and capabilities, we are excited about the potential to enable a faster path for next-generation gene editing therapeutics to CF patients.”

Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis

Retrieved on: 
Thursday, February 15, 2024
Health, Genetics, Other Science, Research, Science, Biotechnology, Therapy, LNP, Liver, MB, CRISPR, Gene editing, Intellia Therapeutics, Messenger, Recode, Cystic fibrosis, Mucus, NTLA, DSM-IV codes, Respiratory failure, Cell, CFTR, Patient, Medicine, Tissue, DNA, Vaccine

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, and ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis (CF).

Key Points: 
  • Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, and ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis (CF).
  • Intellia will be responsible for the design of the editing strategy and research-grade components for the investigational therapies.
  • “This collaboration provides further validation of ReCode's SORT LNP platform to deliver diverse gene editing modalities to specific cells and tissues.
  • By combining our highly synergistic technologies and capabilities, we are excited about the potential to enable a faster path for next-generation gene editing therapeutics to CF patients.”